Thieler Law Corp advises investors with losses exceeding $100,000 of the September 23, 2019 lead plaintiff deadline in a class action lawsuit filed against Karyopharm Therapeutics Inc (NASDAQ: KPTI) (“Karyopharm” or “the Company”). The suit is pending in the U.S. District Court for the District of Massachusetts and investors, who purchased Karyopharm Therapeutics Inc securities between March 2, 2017 and February 22, 2019 and/or pursuant to the April 28, 2017 and May 7, 2018 common stock offerings, have until September 23, 2019 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased Karyopharm Therapeutics Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that throughout the Class Period, the Company continued to tout the commercial prospects for selinexor and consistently described selinexor as having a “predictable and manageable tolerability profile” and a “very nice safety profile,” and assured investors that it was “well tolerated” by patients. Karyopharm also claimed that selinexor had the potential to be used as a new treatment for MM, with limited and manageable side effects. As a result of these misrepresentations, Karyopharm shares traded at artificially inflated prices during the Class Period.

On February 22, 2019 the FDA released a briefing document that expressed serious concerns with selinexor. According to the FDA, one of the previously cancelled selinexor trials had resulted in "worse overall survival" for certain patients treated with selinexor, which "highlight[ed] the toxicity of this drug."  The FDA concluded that "[t]reatment with selinexor is associated with significant toxicity" and has "limited efficacy."

Following this news, NASDAQ: KPTI fell from $8.97 per share on February 21, 2019 to $5.07 on February 22, 2019—a $3.90 or 43.48% drop.

If you were negatively impacted by your investment in Karyopharm Therapeutics Inc securities between March 2, 2017 and February 22, 2019 and/or pursuant to the April 28, 2017 and May 7, 2018 common stock offerings and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/

or

Facsimile: +1 (619) 785 – 3185